SCHEMBL3254872

SCHEMBL3254872

CCOC(=O)c1c[nH]c2c(=O)[nH]c3ccc(S(=O)(=O)Nc4ccccc4C)cc3c12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 7/20 0.51
POLB P06746 7/20 0.51
L3MBTL1 Q9Y468 5/20 0.51
MAPT P10636 5/20 0.51
LMNA P02545 6/20 0.49
TP53 P04637 5/20 0.49
ALDH1A1 P00352 3/20 0.47
KMT2A Q03164 3/20 0.47
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2D6 P10635 2/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2C19 P33261 2/20 0.47
KDM4E B2RXH2 2/20 0.47
MEN1 O00255 1/20 0.47
PKM P14618 1/20 0.47
CASP1 P29466 1/20 0.47
RECQL P46063 1/20 0.47
HSD17B10 Q99714 1/20 0.47
TSHR P16473 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3255485 0.91 ALDH1A1 (0.47) TDP1POLBL3MBTL1MAPTLMNA
SCHEMBL3254789 0.89 PKM (0.51) TDP1POLBMAPTLMNATP53
SCHEMBL3250191 0.89 POLB (0.47) TDP1POLBL3MBTL1MAPTLMNA
SCHEMBL3251813 0.88 POLB (0.47) TDP1POLBL3MBTL1MAPTLMNA
SCHEMBL3248510 0.88 TDP1 (0.55) TDP1POLBL3MBTL1MAPTLMNA
SCHEMBL3250099 0.86 POLB (0.47) TDP1POLBL3MBTL1MAPTLMNA
SCHEMBL3248963 0.86 TAS2R14 (0.44) L3MBTL1MAPTLMNATP53ALDH1A1
SCHEMBL3241955 0.86 MAPT (0.53) TDP1POLBMAPTLMNATP53
SCHEMBL3254167 0.85 MAPT (0.51) TDP1POLBL3MBTL1MAPTLMNA
SCHEMBL3251351 0.85 MEN1 (0.61) TDP1POLBMAPTLMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 TDP1 1098/4885POLB 1007/4885L3MBTL1 4622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.